Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VEGF Trap (Aflibercept) in Acute Myeloid Leukemia
NCT00601991Phase 2Withdrawn
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Mar 2007
- Primary completion
- Mar 2009
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
01
Overview
Phase 2, open-label, single-arm trial of aflibercept in acute myeloid leukemia (AML), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoints: Response Rate and Progression-Free Survival at 12 weeks. Planned start Mar 2007; status: withdrawn.
02
Drugs
aflibercept
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00601991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00601991.